<!DOCTYPE html>
<html lang="en"><head>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-html/tabby.min.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/light-border.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting-37eea08aefeeee20ff55810ff984fec1.css" rel="stylesheet" id="quarto-text-highlighting-styles"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.7.32">

  <title>talks – Sarcopenia in GI Cancers</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="site_libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="site_libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
    /* CSS for citations */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
      margin-bottom: 0em;
    }
    .hanging-indent div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }  </style>
  <link rel="stylesheet" href="site_libs/revealjs/dist/theme/quarto-f563837468303362081e247dddd440d0.css">
  <link href="site_libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="site_libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="site_libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="site_libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" class="quarto-title-block center">
  <h1 class="title">Sarcopenia in GI Cancers</h1>

<div class="quarto-title-authors">
</div>

</section>
<section id="sarcopenia-and-mortality-after-gi-cancer-surgery" class="title-slide slide level1 center">
<h1>Sarcopenia and mortality after GI Cancer Surgery</h1>
<p>Eindhoven cancer registry. Esohpagectomy 90=day mortality 7.1% for &lt;65 years, 8.7% for 65-74 years, and 15.4% for 75+</p>
<p>Mortality should be reported at 90 days Mayo SC, Shore AD, Nathan H, Edil BH, Hirose K, Anders RA, et al.&nbsp;Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford). 2011;13:473–82 Venkat R, Puhan MA, Schulick RD, Cameron JL, Eckhauser FE, Choti MA, et al.&nbsp;Predicting the risk of perioperative mortality in patients undergoing pancreaticoduodenectomy: a novel scoring system. Arch Surg. 2011;146:1277–84 Bryant AS, Rudemiller K, Cerfolio RJ. The 30- versus 90-day operative mortality after pulmonary resection. Ann Thorac Surg. 2010;89: 1717–22; discussion 1722–3</p>
</section>

<section>
<section id="pancreatic-cancer" class="title-slide slide level1 center">
<h1>Pancreatic cancer</h1>
<p>Five-year survival rate 4%</p>
<p>Cachexia is common</p>
<p>Cachexia worsens prognosis in patients with resectable pancreatic cancear (Bachmann JGI Surg 2008)</p>
</section>
<h3 id="peritoperative-morbidity-and-postop-survival">Peritoperative morbidity and postop survival</h3>
<p>Review of body composition in pancreatic cancer <span class="citation" data-cites="bundred1603">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Bundred et al., 2019</a>)</span>. Increased risk of morbidity and mortality after surgery and overall survival after surgery. Nine studies of survival in unresectable cancer shows worse survival in non-sarcopenic patients.</p>
<section id="chemotherapy-toxicity" class="slide level2">
<h2>Chemotherapy Toxicity</h2>
<p>FOLFIRINOX: 82 patients with pancreatic cancer treated with FOLFIRINOX: Shorter survival in sarcopenic patients, especially those with sarcopenia obesity. Worse survival with elevated adipose tissue index (ATI).<span class="citation" data-cites="kurita127">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Kurita et al., 2019</a>)</span></p>
<p>Gemcitabine: <span class="citation" data-cites="tan6973">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Tan et al., 2009</a>)</span></p>
<p>Impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangio <span class="citation" data-cites="rollins1103">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Rollins et al., 2016</a>)</span> No difference in chemotherapy toxicity in 98 metastatic pancreatic cancer patients</p>
<p>Gemcitabine: 330 patients treated with first-line chemotherapy. SMI and SMD prognostic for survival and chemotherapy toxicity.<span class="citation" data-cites="kim77">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Kim et al., 2021</a>)</span> SMI cutpoints of Martin 1539. SMD cutpoints 41 and 33 cm2/m2 for non-overweight and overweight patients.<span class="citation" data-cites="martin1539">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Martin et al., 2013</a>)</span> Low SMI not associated with survival, but low SMD associated with shorter survival. Patients with low SMI and low SMD have worse survival. ECOG, number of metastatic sites, and chemotherapy drug were prognostic. Grace 3/4 toxicity more common in low SMI (59% vs 43%) and in low SMD (44% vs 60%). SMD was a better prognostic factor. No survival difference according to SMD in responders, but worse survival among non-responders based upon SMD.</p>
<p>Review of 12 articles <span class="citation" data-cites="rizzo974116">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Rizzo et al., 2022</a>)</span> 4/12 articles showed an association between body composition and chemotherapy-related toxicity</p>
<p>Korea: Palliative chemotherapy among 484 patients <span class="citation" data-cites="choie0139749">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Choi et al., 2015</a>)</span>. Decrease in SMI was present in 61% of men and 41% of women. Decrease in BMI was seen in 37%. Poor prognosis for men was affected by sarcopenia, decline in SMI. Prognosis of women was worsened by overweight at diagnosis, decline in SMI, and decline in BMI. Sarcopenia defined as &lt;42 in men and &lt;33.9 in women using ROC.</p>
<h3 id="prognostic-value">Prognostic value</h3>
<p>Sarcopenic obesity adverse prognosticator in pancreatic cancer <span class="citation" data-cites="tan6973">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Tan et al., 2009</a>)</span>. 111 patients: 56% sarcopenic, 40% obese, and 16% sarcopenic obesity.</p>
<p>Different outcomes with sarcopenia using Western and Eastern criteria <span class="citation" data-cites="wu862">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Wu et al., 2019</a>)</span>. Taiwan: 146 patients with newly diagnosed pancreatic cancer. Prevalence of sarcopenia was 66% by Western criteria and 11% by Eastern criteria. Patients sarcopenia by Western criteria had no worse survival than non-sarcopenic, but patients sarcopenic by Eastern criteria had worse survival (p=0.008), and on multivariate analysis accounting for stage (p=0.014)</p>
<p>Ozola Zalite I, Zykus R, Francisco Gonzalez M, Saygili F, Pukitis A, Gaujoux S, Charnley RM, Lyadov V. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology.2015;15(1):19–24.</p>
<p>Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, et al.&nbsp;Prognostic factors for risk stratification of patients with recurrent or metastatic pancreatic adenocarcinoma who were treated with gemcitabinebased chemotherapy. Cancer Res Treat. 2016;48(4):1264–73</p>
</section></section>
<section>
<section id="gastric-cancer" class="title-slide slide level1 center">
<h1>Gastric Cancer</h1>
<p>Non-cancer prognosis after gastrectomy in Japan: Male sex, neutrophil-lymphocyte ratio, skeletal muscel index <span class="citation" data-cites="iida753">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Iida et al., 2022</a>)</span></p>
<p>PMID 34774016</p>
</section>
<h3 id="body-composition-and-therapy-of-advanced-gi-cancers">Body composition and therapy of advanced GI Cancers</h3>
<p>Low muscle mass has been shown to be associated with poor prognosis cancer patients.<span class="citation" data-cites="martin1539">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Martin et al., 2013</a>)</span> This may be due to overal frailty or low muscle mass may lead to increased toxicity from chemotherapy due to pharmacokinetic mechanism. 5-FU is hydrophilic and it volume of distribution includes the muscle compartment, while oxaliplatin is hydrophobic, with distribution in the fat compartment<span class="citation" data-cites="bozzetti2107">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Bozzetti, 2017</a>)</span>.</p>
<p>In addition, loss of muscle mass during chemotherapy for advanced cancers is a poor prognosticator.</p>
<p>Blauhoff <span class="citation" data-cites="blauwhoff-buskermolen1339">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Blauwhoff-Buskermolen et al., 2016</a>)</span> studis 67 patients with metastatic colorectal cancer. Muscle area on CT decreased by 6.1% over 3 months. Patients in the lowest tertile (loss of 9%) had worse survial. Overall survival 17.5 months for first-line chemotherapy and 8.5months for second-line. Baseline muscle density was predictive of survival on multivariable analysis, but low SMI at baseline was not associatesd with survival. (This may be because sarcopenic obesity is the major risk factor, and there were few obese patients in the study cohort) &gt;Muscle loss of 9% or more remained independently associated with survival when adjusted for sex, age, baseline lactate dehydrogenase concentration, comorbidity, mono-organ or multiorgan metastases, treatment line, and tumor progression at first evaluation by computed tomography scan (hazard ratio, 4.47; 95% CI, 2.21 to 9.05; P , .001). We found a mean coefficient of variation between observers of 0.6% for skeletal muscle area in a random sample of 20 patients, which is regarded to be low.<span class="citation" data-cites="macdonald342">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">MacDonald et al., 2011</a>)</span>. Changes between the first and second scans were calculated as a rate of change per 3 months, meaning change per first evaluation, to compare with available literature.[awad74][prado1583]Relative muscle change per 3 months was categorized into tertiles of muscle change: tertile one, highest muscle loss up to 9%; tertile two, muscle loss of 9% to 1.5%; and tertile three, muscle loss of 1.5% until highest gain in muscle. However, the survival curve of tertile two was not significantly different from the survival curve of tertile three (log-rank P = .961); therefore tertiles two and three were pooled (cutoff, 9% muscle loss).</p>
<p>Awad <span class="citation" data-cites="awad74">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Awad et al., 2012</a>)</span>studies changes in body composition during neodjuvant chemotherapy for esophagogastric cancer.</p>
<p>Kurk <span class="citation" data-cites="kurk1033">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Kurk et al., 2020</a>)</span> found that skeletal muscle loss during chemotherapy was associated with decreased progression-free and overall- survival in metastatic colorectal cancer.</p>
<blockquote>
<p>Detailed changes in skeletal muscle mass and body weight during CAIRO3 treatments were previously reported.KurkS, p909, 2018) We additionally analyzed changes in SMI and BMI during these treatments by linear mixed effects models.(Bayar MA,p311,2017) The baseline value of the outcome (SMI/BMI) was included in the outcome vector. Potential confounders were age, sex, lactate dehydrogenase (LDH) levels, best response to initial six cycles CAPOX‐B, resection of the primary tumor, and the number of metastatic sites. The final model was selected based on the Akaike Information Criterion (AIC) and included: treatment arm, time, age, sex, resection primary tumor, and the interaction of treatment arm by time as fixed effects. Modeling time as a random effect did not increase the model fit as indicated by the AIC. To investigate differences in SMI and BMI changes over time between the CAIRO3 treatment arms, we checked the significance of the two‐way interaction including treatment arm by time.</p>
</blockquote>
<blockquote>
<p>During p2 (maintenance CAP‐B/observation), again absolute SMI and BMI at the start (t1) of treatment were not associated with early progression and death. In contrast, SMI loss and BMI loss during treatment were associated with early progression and death.</p>
</blockquote>
<p>Fogelman <span class="citation" data-cites="fogelman307">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Fogelman et al., 2014</a>)</span> treated patients undergoing chemotherapy with a novel agent designed to reduce muscle less. CT scans at 2 months were compared with baseline scans prior to chemotherapy.</p>
<blockquote>
<p>Changes in skeletal muscle were determined using routinely acquired CT scans for patients on the study. We calculated skeletal muscle cross-sectional area (cm2) at the third lumbar vertebra (L3). A single slice at the mid-point of L3 was used, preferably a 2.5-mm slice if available, and a 5-mm slice if a 2.5-mm slice was not available. The L3 is a landmark that has been extensively used and validated in studies assessing body composition in cancer patients [<span class="citation" data-cites="shen2333">Shen et al. (<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">2004</a>)</span>]<span class="citation" data-cites="prado269">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Prado et al., 2009</a>)</span> . Skeletal muscle surface areas were determined using Slice-o-Matic softwareTM, version 4.3 (Tomovision, Montreal, QC, Canada) using pre-established thresholds of Hounsfield units (HU) of −29 to +150 <span class="citation" data-cites="mitsiopoulos115">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Mitsiopoulos et al., 1998</a>)</span>. We additionally evaluated adipose tissue cross-sectional area (subcutaneous, visceral, and intramuscular) in the L3 region as described previously <span class="citation" data-cites="mourtzakis997">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Mourtzakis et al., 2008</a>)</span>. Changes in muscle and adipose tissue surface areas over time were determined for each patient from the baseline study to the first CT post treatment, done after 2 months. We looked at muscle loss as a continuous variable and defined “meaningful loss” as greater than a 6 cm2 difference from the baseline to the second scan. We chose this cut point as it is equivalent to 1 kg of skeletal muscle and is associated with physical function (i.e., muscle strength). Additionally, this cut point has been used to investigate significant changes in muscle mass throughout cancer disease trajectory [<span class="citation" data-cites="shen2333">Shen et al. (<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">2004</a>)</span>]<span class="citation" data-cites="frontera1038">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Frontera et al., 1988</a>)</span><span class="citation" data-cites="prado1012">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Prado et al., 2013</a>)</span>.</p>
</blockquote>
<p>Prado <span class="citation" data-cites="prado1012">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Prado et al., 2013</a>)</span> looked at changes in 1279 CT scans in 368 patients with advanced cancer. The last available interval with CT scans was chosen for comparison. Categorized into stable, gaining, losing for muscle and for adipose tissue. Adipose tissue was ?? sum of visceral adipose tissue and subcutaneous tissue. (<strong>Did not use SMI</strong>). Muscel loss and adipose loss seemed correlated, with larger magnitude of adipose tissue loss at short interval to death. (Authors conclusion that muscle and adipose tissue loss in the past 3 months of life is likely not possible) &gt;Advanced-cancer patients (n = 368; median survival: 196 d) had a total of 1279 CT images over the course of their disease. With consideration of all time points, muscle loss occurred in 39% of intervals between any 2 scans. However, the overall frequency of muscle gain was 15.4%, and muscle was stable in 45.6% of intervals between any 2 scans, which made the maintenance or gain of muscle the predominant behavior. Multinomial logistic regression revealed that being within 90 d (compared with &gt;90 d) from death was the principal risk factor for muscle loss (OR: 2.67; 95% CI: 1.45, 4.94; P = 0.002), and muscle gain was correspondingly less likely (OR: 0.37; 95% CI: 0.20, 0.69; P = 0.002) at this time. Sex, age, BMI, and tumor group were not significant predictors of muscle loss or gain. A much higher proportion of men (61%) than women (31%) met the criteria for sarcopenia. Changes in muscle and adipose tissue over time were calculated as the absolute loss or gain of tissue area during each scan interval. The precision error of measurements was ~1.5% <span class="citation" data-cites="mourtzakis997">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Mourtzakis et al., 2008</a>)</span> with a minimum detectable change of ~3 cm2. We attributed the change during each interval into the following categories: 1) muscle loss ≥6.0 cm2, 2) stable muscle ±5.9 cm2, or 3) muscle gain ≥6.0cm2. These cutoffs are equivalent to a loss or gain of ≥1 kg of skeletal muscle on a whole-body basis and are associated with alterations in muscle strength [<span class="citation" data-cites="shen2333">Shen et al. (<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">2004</a>)</span>]<span class="citation" data-cites="frontera1038">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Frontera et al., 1988</a>)</span>. For adipose tissue, categories were based on the equivalence of 14.7 cm2 total fat at L3 and 1 kg tissue on a whole-body basis <span class="citation" data-cites="shen2333">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Shen et al., 2004</a>)</span>; therefore, changes during each interval were categorized as 1) adipose tissue loss ≥14.7 cm2, 2) stable adipose tissue ±14.6 cm2, or 3) adipose tissue gain ≥14.7 cm2. CT scans were taken for the diagnosis, confirmation of stage, and follow-up of disease progression and treatment. With the understanding that cachexia evolves markedly in the end of life and to take advantage of repeated measures, we focused on patients with ≥2 CT images (2–6 images) on record during the year preceding their deaths (n = 368). A selection bias was not apparent in this sample; we showed that the sex distribution, age at death, survival time, primary tumor site, tumor morphology, and body-composition features (ie, muscle and adipose tissues) in patients who had only a single scan were not different from those of the overall cohort at an equal time to death (P &gt; 0.1). Patients included in the analysis (n = 368) were of advanced stage, and the median time to death of all groups was &lt;1 y.</p>
<p>Similar study by Tan looking at longitudinal body composition in pancreatic cancer <span class="citation" data-cites="tan6973">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Tan et al., 2009</a>)</span>. 111 patients with metastatic pancreatic cancer: 44 identified with more than one scan. Patients who underwent repeated CT scans were more likely to receive active therapy (71%) and had longer survival than those who had a solitary CT scan (28% receiving active chemotherapy). OVeral median survival 130 days. Age and sarcopenic obesity predicted survival. Sarcopenic obesity had survival of 55 days vs 148 days for those without sarcopenia obesity. Muscle loss was normalized to percent during 100 days. Median interval between scans was ??135 days. Patients grouped in tertiles for muscle gain/loss. Top tertile gained 7% muscle cross-sectional area/100 days, while bottom tertile lost 12% over 100 days. All tertiles lost adipose tissue. <strong>No difference in survival between the tertiles.</strong> &gt; muscle loss was the prevalent behavior, but 14% of patients with metastatic pancreatic cancer (considered the disease most highly associated with cachexia) exhibited a muscle gain of 7.9 ± 14.4%/100 d).</p>
<p>Lieffers and advanced colorectal cancer: Found liver and spleen increased in size in terminal patients (causing increase in basal metabolic rate). Found more rapid muscle loss with progressive disease <span class="citation" data-cites="lieffers1173">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Lieffers et al., 2009</a>)</span>. Different thresholds for VAT (-150 to -50) and SAT(-190 to -30). Also estimated muscel surface area using measurements 5cm above L4<span class="citation" data-cites="shen2333">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Shen et al., 2004</a>)</span>. Most rapid change in body composition between 4 months and 1 month prior to death. &gt;14% of patients gained skeletal muscle during the year preceding death from colorectal cancer (+4.7 ± 5.4%/100 d).</p>
<p>Longitudinal study of patients with advanced non-small cell lung cancer (all with &lt;1yr survival). <span class="citation" data-cites="baracos1133S">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Baracos et al., 2010</a>)</span> &gt;At referral (median time to death: 265 d), mean body mass index (BMI; in kg/m(2)) was 24.9, with 47.4% of patients being overweight or obese. Only 7.5% overall were underweight as conventionally understood (BMI &lt; 18.5). Analysis of computed tomography images showed extremely high heterogeneity of muscle mass within all strata of BMI. The overall prevalence of severe muscle depletion (sarcopenia) was 46.8% and was present in patients in all BMI categories.</p>
<p>Caan <span class="citation" data-cites="caan1008">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Caan et al., 2017</a>)</span> examined body composition and survival from colorecal cncer at Kaiser.</p>
<section id="sarcopenia-and-egs-surgery" class="slide level2 smaller scrollable">
<h2>Sarcopenia and EGS Surgery</h2>
<p>Necrotizing soft-tissue infections <span class="citation" data-cites="castillo-angeles31">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Castillo-Angeles et al., 2022</a>)</span></p>
<p>Ambominal and emergency surgery <span class="citation" data-cites="hajibandeh370">(<a href="#/sarcopenia-and-egs-surgery" role="doc-biblioref" onclick="">Hajibandeh et al., 2019</a>)</span></p>


<div id="refs" class="references csl-bib-body hanging-indent" data-entry-spacing="0" role="list">
<div id="ref-awad74" class="csl-entry" role="listitem">
Awad, S., Tan, B.H., Cui, H., Bhalla, A., Fearon, K.C.H., Parsons, S.L., Catton, J.A., Lobo, D.N., 2012. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clinical Nutrition (Edinburgh, Scotland) 31, 74–77. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/21875767">21875767</a>
</div>
<div id="ref-baracos1133S" class="csl-entry" role="listitem">
Baracos, V.E., Reiman, T., Mourtzakis, M., Gioulbasanis, I., Antoun, S., 2010. Body composition in patients with non-small cell lung cancer: A contemporary view of cancer cachexia with the use of computed tomography image analysis. The American Journal of Clinical Nutrition 91, 1133S–1137S. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/20164322">20164322</a>
</div>
<div id="ref-blauwhoff-buskermolen1339" class="csl-entry" role="listitem">
Blauwhoff-Buskermolen, S., Versteeg, K.S., Schueren, M.A.E. de van der, Braver, N.R. den, Berkhof, J., Langius, J.A.E., Verheul, H.M.W., 2016. Loss of <span>Muscle</span> <span>Mass</span> <span>During</span> <span>Chemotherapy</span> <span>Is</span> <span>Predictive</span> for <span>Poor</span> <span>Survival</span> of <span>Patients</span> <span>With</span> <span>Metastatic</span> <span>Colorectal</span> <span>Cancer</span>. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 34, 1339–1344. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/26903572">26903572</a>
</div>
<div id="ref-bozzetti2107" class="csl-entry" role="listitem">
Bozzetti, F., 2017. Forcing the vicious circle: Sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Annals of Oncology: Official Journal of the European Society for Medical Oncology 28, 2107–2118. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/28911059">28911059</a>
</div>
<div id="ref-bundred1603" class="csl-entry" role="listitem">
Bundred, J., Kamarajah, S.K., Roberts, K.J., 2019. <a href="https://doi.org/10.1016/j.hpb.2019.05.018">Body composition assessment and sarcopenia in patients with pancreatic cancer: A systematic review and meta-analysis</a>. HPB 21, 1603–1612.
</div>
<div id="ref-caan1008" class="csl-entry" role="listitem">
Caan, B.J., Meyerhardt, J.A., Kroenke, C.H., Alexeeff, S., Xiao, J., Weltzien, E., Feliciano, E.C., Castillo, A.L., Quesenberry, C.P., Kwan, M.L., Prado, C.M., 2017. Explaining the <span>Obesity</span> <span>Paradox</span>: <span>The</span> <span>Association</span> between <span>Body</span> <span>Composition</span> and <span>Colorectal</span> <span>Cancer</span> <span>Survival</span> (<span>C</span>-<span>SCANS</span> <span>Study</span>). Cancer Epidemiology, Biomarkers &amp; Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 26, 1008–1015. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/28506965">28506965</a>
</div>
<div id="ref-castillo-angeles31" class="csl-entry" role="listitem">
Castillo-Angeles, M., Uyeda, J.W., Seshadri, A.J., Ramsis, R., Okafor, B.U., Nitzschke, S., Rangel, E.L., Saillant, N.N., Salim, A., Askari, R., 2022. Sarcopenia <span>Is</span> <span>Associated</span> <span>With</span> <span>Increased</span> <span>Mortality</span> in <span>Patients</span> <span>With</span> <span>Necrotizing</span> <span>Soft</span> <span>Tissue</span> <span>Infections</span>. The Journal of Surgical Research 276, 31–36. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/35334381">35334381</a>
</div>
<div id="ref-choie0139749" class="csl-entry" role="listitem">
Choi, Y., Oh, D.-Y., Kim, T.-Y., Lee, K.-H., Han, S.-W., Im, S.-A., Kim, T.-Y., Bang, Y.-J., 2015. Skeletal <span>Muscle</span> <span>Depletion</span> <span>Predicts</span> the <span>Prognosis</span> of <span>Patients</span> with <span>Advanced</span> <span>Pancreatic</span> <span>Cancer</span> <span>Undergoing</span> <span>Palliative</span> <span>Chemotherapy</span>, <span>Independent</span> of <span>Body</span> <span>Mass</span> <span>Index</span>. PloS One 10, e0139749. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/26437072">26437072</a>
</div>
<div id="ref-fogelman307" class="csl-entry" role="listitem">
Fogelman, D.R., Holmes, H., Mohammed, K., Katz, M.H.G., Prado, C.M., Lieffers, J., Garg, N., Varadhachary, G.R., Shroff, R., Overman, M.J., Garrett, C., Wolff, R.A., Javle, M., 2014. Does <span>IGFR1</span> inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? Journal of Cachexia, Sarcopenia and Muscle 5, 307–313. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/24740741">24740741</a>
</div>
<div id="ref-frontera1038" class="csl-entry" role="listitem">
Frontera, W.R., Meredith, C.N., O’Reilly, K.P., Knuttgen, H.G., Evans, W.J., 1988. Strength conditioning in older men: Skeletal muscle hypertrophy and improved function. Journal of Applied Physiology (Bethesda, Md.: 1985) 64, 1038–1044. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/3366726">3366726</a>
</div>
<div id="ref-hajibandeh370" class="csl-entry" role="listitem">
Hajibandeh, S., Hajibandeh, S., Jarvis, R., Bhogal, T., Dalmia, S., 2019. Meta-analysis of the effect of sarcopenia in predicting postoperative mortality in emergency and elective abdominal surgery. The Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 17, 370–380. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/30389220">30389220</a>
</div>
<div id="ref-iida753" class="csl-entry" role="listitem">
Iida, M., Takeda, S., Nakashima, C., Nishiyama, M., Watanabe, Y., Suzuki, N., Yoshino, S., Nakagami, Y., Tanabe, T., Nagano, H., 2022. Risk factors for non-gastric-cancer-related death after gastrectomy in elderly patients. Annals of Gastroenterological Surgery 6, 753–766. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/36338595">36338595</a>
</div>
<div id="ref-kim77" class="csl-entry" role="listitem">
Kim, I.-H., Choi, M.H., Lee, I.S., Hong, T.H., Lee, M.Ah., 2021. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: A retrospective observational study. BMC Cancer 21, 77. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/33461517">33461517</a>
</div>
<div id="ref-kurita127" class="csl-entry" role="listitem">
Kurita, Y., Kobayashi, N., Tokuhisa, M., Goto, A., Kubota, K., Endo, I., Nakajima, A., Ichikawa, Y., 2019. <a href="https://doi.org/10.1016/j.pan.2018.11.001">Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving <span>FOLFIRINOX</span> chemotherapy</a>. Pancreatology 19, 127–135.
</div>
<div id="ref-kurk1033" class="csl-entry" role="listitem">
Kurk, S.A., Peeters, P.H.M., Dorresteijn, B., Jong, P.A. de, Jourdan, M., Creemers, G.-J.M., Erdkamp, F.L.G., Jongh, F.E. de, Kint, P.A.M., Poppema, B.J., Radema, S.A., Simkens, L.H.J., Tanis, B.C., Tjin-A-Ton, M.L.R., Van Der Velden, A., Punt, C.J.A., Koopman, M., May, A.M., 2020. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: <span>Secondary</span> analysis of the phase 3 <span>CAIRO3</span> trial. Cancer Medicine 9, 1033–1043. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/31850687">31850687</a>
</div>
<div id="ref-lieffers1173" class="csl-entry" role="listitem">
Lieffers, J.R., Mourtzakis, M., Hall, K.D., McCargar, L.J., Prado, C.M.M., Baracos, V.E., 2009. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: Contributions of organ and tumor mass to whole-body energy demands. The American Journal of Clinical Nutrition 89, 1173–1179. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/19244378">19244378</a>
</div>
<div id="ref-macdonald342" class="csl-entry" role="listitem">
MacDonald, A.J., Greig, C.A., Baracos, V., 2011. The advantages and limitations of cross-sectional body composition analysis. Current Opinion in Supportive and Palliative Care 5, 342–349. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/21986910">21986910</a>
</div>
<div id="ref-martin1539" class="csl-entry" role="listitem">
Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., Murphy, R., Ghosh, S., Sawyer, M.B., Baracos, V.E., 2013. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 31, 1539–1547. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/23530101">23530101</a>
</div>
<div id="ref-mitsiopoulos115" class="csl-entry" role="listitem">
Mitsiopoulos, N., Baumgartner, R.N., Heymsfield, S.B., Lyons, W., Gallagher, D., Ross, R., 1998. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. Journal of Applied Physiology (Bethesda, Md.: 1985) 85, 115–122. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/9655763">9655763</a>
</div>
<div id="ref-mourtzakis997" class="csl-entry" role="listitem">
Mourtzakis, M., Prado, C.M.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E., 2008. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme 33, 997–1006. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/18923576">18923576</a>
</div>
<div id="ref-prado269" class="csl-entry" role="listitem">
Prado, C.M.M., Birdsell, L.A., Baracos, V.E., 2009. The emerging role of computerized tomography in assessing cancer cachexia. Current Opinion in Supportive and Palliative Care 3, 269–275. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/19667996">19667996</a>
</div>
<div id="ref-prado1012" class="csl-entry" role="listitem">
Prado, C.M., Sawyer, M.B., Ghosh, S., Lieffers, J.R., Esfandiari, N., Antoun, S., Baracos, V.E., 2013. Central tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential? The American Journal of Clinical Nutrition 98, 1012–1019. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/23966429">23966429</a>
</div>
<div id="ref-rizzo974116" class="csl-entry" role="listitem">
Rizzo, S., Scala, I., Robayo, A.R., Cefalì, M., De Dosso, S., Cappio, S., Xhepa, G., Del Grande, F., 2022. Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: <span>A</span> systematic review. Frontiers in Oncology 12, 974116. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/36249069">36249069</a>
</div>
<div id="ref-rollins1103" class="csl-entry" role="listitem">
Rollins, K.E., Tewari, N., Ackner, A., Awwad, A., Madhusudan, S., Macdonald, I.A., Fearon, K.C.H., Lobo, D.N., 2016. <a href="https://doi.org/10.1016/j.clnu.2015.08.005">The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma</a>. Clinical Nutrition 35, 1103–1109.
</div>
<div id="ref-shen2333" class="csl-entry" role="listitem">
Shen, W., Punyanitya, M., Wang, Z., Gallagher, D., St-Onge, M.-P., Albu, J., Heymsfield, S.B., Heshka, S., 2004. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. Journal of Applied Physiology (Bethesda, Md.: 1985) 97, 2333–2338. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/15310748">15310748</a>
</div>
<div id="ref-tan6973" class="csl-entry" role="listitem">
Tan, B.H.L., Birdsell, L.A., Martin, L., Baracos, V.E., Fearon, K.C.H., 2009. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15, 6973–6979. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/19887488">19887488</a>
</div>
<div id="ref-wu862" class="csl-entry" role="listitem">
Wu, C.-H., Chang, M.-C., Lyadov, V.K., Liang, P.-C., Chen, C.-M., Shih, T.T.-F., Chang, Y.-T., 2019. Comparing <span>Western</span> and <span>Eastern</span> criteria for sarcopenia and their association with survival in patients with pancreatic cancer. Clinical Nutrition (Edinburgh, Scotland) 38, 862–869. https://vb3lk7eb4t.search.serialssolutions.com/?id=<a href="https://www.ncbi.nlm.nih.gov/pubmed/29503056">29503056</a>
</div>
</div>
</section></section>
    </div>
  <div class="quarto-auto-generated-content" style="display: none;">
<div class="footer footer-default">

</div>
</div></div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="site_libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="site_libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="site_libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="site_libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="site_libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="site_libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="site_libs/revealjs/plugin/notes/notes.js"></script>
  <script src="site_libs/revealjs/plugin/search/search.js"></script>
  <script src="site_libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="site_libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': true,
'previewLinksAuto': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'jumpToSlide': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleScrollView(event)\"><kbd>r</kbd> Scroll View Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"5\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: false,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: false,

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'none',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'default',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
      window.document.addEventListener("DOMContentLoaded", function (event) {
        const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
        tabsets.forEach(function(tabset) {
          const tabby = new Tabby('#' + tabset.id);
        });
        const isCodeAnnotation = (el) => {
          for (const clz of el.classList) {
            if (clz.startsWith('code-annotation-')) {                     
              return true;
            }
          }
          return false;
        }
        const onCopySuccess = function(e) {
          // button target
          const button = e.trigger;
          // don't keep focus
          button.blur();
          // flash "checked"
          button.classList.add('code-copy-button-checked');
          var currentTitle = button.getAttribute("title");
          button.setAttribute("title", "Copied!");
          let tooltip;
          if (window.bootstrap) {
            button.setAttribute("data-bs-toggle", "tooltip");
            button.setAttribute("data-bs-placement", "left");
            button.setAttribute("data-bs-title", "Copied!");
            tooltip = new bootstrap.Tooltip(button, 
              { trigger: "manual", 
                customClass: "code-copy-button-tooltip",
                offset: [0, -8]});
            tooltip.show();    
          }
          setTimeout(function() {
            if (tooltip) {
              tooltip.hide();
              button.removeAttribute("data-bs-title");
              button.removeAttribute("data-bs-toggle");
              button.removeAttribute("data-bs-placement");
            }
            button.setAttribute("title", currentTitle);
            button.classList.remove('code-copy-button-checked');
          }, 1000);
          // clear code selection
          e.clearSelection();
        }
        const getTextToCopy = function(trigger) {
            const codeEl = trigger.previousElementSibling.cloneNode(true);
            for (const childEl of codeEl.children) {
              if (isCodeAnnotation(childEl)) {
                childEl.remove();
              }
            }
            return codeEl.innerText;
        }
        const clipboard = new window.ClipboardJS('.code-copy-button:not([data-in-quarto-modal])', {
          text: getTextToCopy
        });
        clipboard.on('success', onCopySuccess);
        if (window.document.getElementById('quarto-embedded-source-code-modal')) {
          const clipboardModal = new window.ClipboardJS('.code-copy-button[data-in-quarto-modal]', {
            text: getTextToCopy,
            container: window.document.getElementById('quarto-embedded-source-code-modal')
          });
          clipboardModal.on('success', onCopySuccess);
        }
          var localhostRegex = new RegExp(/^(?:http|https):\/\/localhost\:?[0-9]*\//);
          var mailtoRegex = new RegExp(/^mailto:/);
            var filterRegex = new RegExp("https:\/\/gisurgonc\.github\.io\/talks\/");
          var isInternal = (href) => {
              return filterRegex.test(href) || localhostRegex.test(href) || mailtoRegex.test(href);
          }
          // Inspect non-navigation links and adorn them if external
         var links = window.document.querySelectorAll('a[href]:not(.nav-link):not(.navbar-brand):not(.toc-action):not(.sidebar-link):not(.sidebar-item-toggle):not(.pagination-link):not(.no-external):not([aria-hidden]):not(.dropdown-item):not(.quarto-navigation-tool):not(.about-link)');
          for (var i=0; i<links.length; i++) {
            const link = links[i];
            if (!isInternal(link.href)) {
              // undo the damage that might have been done by quarto-nav.js in the case of
              // links that we want to consider external
              if (link.dataset.originalHref !== undefined) {
                link.href = link.dataset.originalHref;
              }
            }
          }
        function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
          const config = {
            allowHTML: true,
            maxWidth: 500,
            delay: 100,
            arrow: false,
            appendTo: function(el) {
                return el.closest('section.slide') || el.parentElement;
            },
            interactive: true,
            interactiveBorder: 10,
            theme: 'light-border',
            placement: 'bottom-start',
          };
          if (contentFn) {
            config.content = contentFn;
          }
          if (onTriggerFn) {
            config.onTrigger = onTriggerFn;
          }
          if (onUntriggerFn) {
            config.onUntrigger = onUntriggerFn;
          }
            config['offset'] = [0,0];
            config['maxWidth'] = 700;
          window.tippy(el, config); 
        }
        const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
        for (var i=0; i<noterefs.length; i++) {
          const ref = noterefs[i];
          tippyHover(ref, function() {
            // use id or data attribute instead here
            let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
            try { href = new URL(href).hash; } catch {}
            const id = href.replace(/^#\/?/, "");
            const note = window.document.getElementById(id);
            if (note) {
              return note.innerHTML;
            } else {
              return "";
            }
          });
        }
        const findCites = (el) => {
          const parentEl = el.parentElement;
          if (parentEl) {
            const cites = parentEl.dataset.cites;
            if (cites) {
              return {
                el,
                cites: cites.split(' ')
              };
            } else {
              return findCites(el.parentElement)
            }
          } else {
            return undefined;
          }
        };
        var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
        for (var i=0; i<bibliorefs.length; i++) {
          const ref = bibliorefs[i];
          const citeInfo = findCites(ref);
          if (citeInfo) {
            tippyHover(citeInfo.el, function() {
              var popup = window.document.createElement('div');
              citeInfo.cites.forEach(function(cite) {
                var citeDiv = window.document.createElement('div');
                citeDiv.classList.add('hanging-indent');
                citeDiv.classList.add('csl-entry');
                var biblioDiv = window.document.getElementById('ref-' + cite);
                if (biblioDiv) {
                  citeDiv.innerHTML = biblioDiv.innerHTML;
                }
                popup.appendChild(citeDiv);
              });
              return popup.innerHTML;
            });
          }
        }
      });
      </script>
    

</body></html>